| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors
|
Tolcher, A.W.
|
|
|
30 |
S1 |
p. i2
|
article
|
| 2 |
Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials
|
Varga, A.
|
|
|
30 |
S1 |
p. i2
|
article
|
| 3 |
ATM loss in NSCLC increases sensitivity to cisplatin and PARP inhibition
|
Bebb, D.G.
|
|
|
30 |
S1 |
p. i6
|
article
|
| 4 |
Butein inhibits solid tumors cell viability, colony, and tumor growth via STAT3 signaling pathway and enhance the anti-cancer effects of Frondoside-A and camptothecin
|
Attoub, S.
|
|
|
30 |
S1 |
p. i6
|
article
|
| 5 |
Choline transporter-like protein 1 (CTL1/SLC44A1) is a therapeutic target molecule for prostate cancer therapy
|
Inazu, M.
|
|
|
30 |
S1 |
p. i7
|
article
|
| 6 |
Clinical correlation between different CKIT exon mutations and clinical outcome imatinib mesylate treatment in gastrointestinal stromal tumor (GIST) patients
|
Zakaria, G.Y.
|
|
|
30 |
S1 |
p. i13
|
article
|
| 7 |
Comprehensive genomic profiling of Chinese esophageal squamous cell carcinoma patients
|
Ji, Y.
|
|
|
30 |
S1 |
p. i12
|
article
|
| 8 |
Detection of genomic alterations in breast cancer (BC) patients with paired plasma and tumour specimens
|
Yap, Y.S.
|
|
|
30 |
S1 |
p. i10
|
article
|
| 9 |
Drug Index
|
|
|
|
30 |
S1 |
p. i15
|
article
|
| 10 |
Dynamic change in the distribution of cancer types in oncology phase I trials
|
Sato, J.
|
|
|
30 |
S1 |
p. i12
|
article
|
| 11 |
Editorial board
|
|
|
|
30 |
S1 |
p. ii-iii
|
article
|
| 12 |
Enhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7
|
Xie, Y.
|
|
|
30 |
S1 |
p. i13
|
article
|
| 13 |
Establishment and application of a panel of PBMC-humanized mouse tumor models in cancer immunotherapy
|
Bourre, L.
|
|
|
30 |
S1 |
p. i3
|
article
|
| 14 |
Evaluation of magnetic nanoparticle of irinotecan for personalized treatment of colorectal cancer
|
Singh, A.V.
|
|
|
30 |
S1 |
p. i8
|
article
|
| 15 |
Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications
|
Reinhold, W.
|
|
|
30 |
S1 |
p. i14
|
article
|
| 16 |
Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash
|
Hirata, T.
|
|
|
30 |
S1 |
p. i13
|
article
|
| 17 |
Inhibition of PDE4 sensitizes drug resistant NSCLC to TKI therapy
|
Mukherjee, S.
|
|
|
30 |
S1 |
p. i6
|
article
|
| 18 |
Matricellular protein CCN3/NOV regulates tumorigenesis in triple-negative breast cancer
|
Son, S.
|
|
|
30 |
S1 |
p. i8
|
article
|
| 19 |
microRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1–pRb–E2F1 pathway in prostate cancer cells
|
Gan, L.
|
|
|
30 |
S1 |
p. i7
|
article
|
| 20 |
Nischarin expression in colon cancer
|
Cavic, M.
|
|
|
30 |
S1 |
p. i7-i8
|
article
|
| 21 |
Novel applications of MVA to improve outcomes in immunooncology
|
Heery, C.
|
|
|
30 |
S1 |
p. i3
|
article
|
| 22 |
Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
|
Hollebecque, A.
|
|
|
30 |
S1 |
p. i4
|
article
|
| 23 |
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
|
Umapathy, G.
|
|
|
30 |
S1 |
p. i6
|
article
|
| 24 |
Photosensitizer-based multimodal nanocomposites as a theranostic agent for near infrared (NIR)-guided cancer-targeting synergistic chemo-phototherapy
|
Ponraj, T.
|
|
|
30 |
S1 |
p. i5
|
article
|
| 25 |
PIWI proteins play oncogenic functions in pancreatic cancer
|
Li, W.
|
|
|
30 |
S1 |
p. i1
|
article
|
| 26 |
Preclinical drug testing and clinical trial planning of palbociclib (CDK4/6 inhibitor) drug combination with a PI3K or MAPK inhibitor for colorectal cancer (CRC)
|
Lee, C.L.
|
|
|
30 |
S1 |
p. i7
|
article
|
| 27 |
Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors
|
Amaral, S.R.
|
|
|
30 |
S1 |
p. i3
|
article
|
| 28 |
Proteomic analysis of UKF-NB-4 cells reveals a stimulatory activity of MT-3 on cellular senescence and apoptosis
|
Merlos Rodrigo, M.A.
|
|
|
30 |
S1 |
p. i13
|
article
|
| 29 |
Reactive oxygen species and vascular endothelial growth factor (VEGF) in ovarian cancer patients
|
Trifanescu, O.G.
|
|
|
30 |
S1 |
p. i8-i9
|
article
|
| 30 |
Safety profile and therapeutic efficacy of one cycle of [177Lu]prostate-specific membrane antigen (PSMA) in end stage metastatic castration-resistant prostate cancer patients with low performance status
|
Gupta, M.
|
|
|
30 |
S1 |
p. i4-i5
|
article
|
| 31 |
Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?
|
Leroy, L.
|
|
|
30 |
S1 |
p. i5
|
article
|
| 32 |
Simultaneous unbiased and absolute quantification of a 500 protein panel in pancreatic cancer plasma using HRM mass spectrometry
|
Yu, H.
|
|
|
30 |
S1 |
p. i10-i11
|
article
|
| 33 |
Structural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels
|
El-Layeh, R.A.
|
|
|
30 |
S1 |
p. i14
|
article
|
| 34 |
Table of Contents
|
|
|
|
30 |
S1 |
p. iv
|
article
|
| 35 |
Targeting HIF1α/AP1 in hypoxia by novel 7-amino-6-halogeno-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides
|
Scherbakov, A.M.
|
|
|
30 |
S1 |
p. i5
|
article
|
| 36 |
Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy
|
Wang, M.
|
|
|
30 |
S1 |
p. i10
|
article
|
| 37 |
Therapeutic potential of connective tissue growth factor (CTGF) in triple-negative breast cancer
|
Kim, H.
|
|
|
30 |
S1 |
p. i8
|
article
|
| 38 |
The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer
|
de Rojas, T.
|
|
|
30 |
S1 |
p. i12
|
article
|
| 39 |
Translational Research Index
|
|
|
|
30 |
S1 |
p. i16
|
article
|
| 40 |
Use of CTTA to predict treatment response in patients with EGFR T790M+ NSCLC treated with osimertinib
|
Tan, W.L.
|
|
|
30 |
S1 |
p. i10
|
article
|
| 41 |
89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors
|
Giesen, D.
|
|
|
30 |
S1 |
p. i4
|
article
|
Journal description